| 41 0.64 (1.59%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 50.4  |
1-year : | 52.54 |
| Resists | First : | 43.15 |
Second : | 44.99 |
| Pivot price | 41.6 |
|||
| Supports | First : | 40.18 |
Second : | 33.42 |
| MAs | MA(5) : | 40.74 |
MA(20) : | 42.01 |
| MA(100) : | 43.74 |
MA(250) : | 44.5 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 7.6 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 51.03 | Low : | 36.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IRMD ] has closed above bottom band by 30.8%. Bollinger Bands are 30.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.47 - 41.7 | 41.7 - 41.92 |
| Low: | 39.57 - 39.87 | 39.87 - 40.15 |
| Close: | 40.56 - 41 | 41 - 41.4 |
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Tue, 16 Apr 2024
IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates - Yahoo Lifestyle Australia
Fri, 12 Apr 2024
(IRMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Tue, 02 Apr 2024
Iradimed Corporation (NASDAQ:IRMD) Short Interest Update - MarketBeat
Mon, 01 Apr 2024
IRadimed shares get price target bump on growth outlook - Investing.com
Sat, 23 Mar 2024
IRMD Stock Quote Price and Forecast - CNN
Sun, 11 Feb 2024
Institutional investors own a significant stake of 39% in IRadimed Corporation (NASDAQ:IRMD) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 13 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 37 (%) |
| Held by Institutions | 51.6 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 102 (K) |
| EPS | 1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 26.2 % |
| Operating Margin | 29.5 % |
| Return on Assets (ttm) | 14.1 % |
| Return on Equity (ttm) | 23.7 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.17 |
| EBITDA (p.s.) | 1.64 |
| Qtrly Earnings Growth | 23.1 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | 30.37 |
| PEG Ratio | 1.5 |
| Price to Book value | 7.26 |
| Price to Sales | 7.91 |
| Price to Cash Flow | 38.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|